Cargando…

Transplacental passage of vancomycin in the ex vivo human perfusion model.

OBJECTIVES: To determine maternal-fetal transplacental passage of vancomycin in the ex vivo human placental perfusion model. METHODS: Six term placentas were collected immediately after delivery and perfused with physiologic medium using the single cotyledon perfusion system. Vancomycin was added to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hnat, Michael D, Gainer, Julie, Bawdon, Roger E, Wendel, George D
Formato: Texto
Lenguaje:English
Publicado: 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784591/
https://www.ncbi.nlm.nih.gov/pubmed/15739818
_version_ 1782132054315499520
author Hnat, Michael D
Gainer, Julie
Bawdon, Roger E
Wendel, George D
author_facet Hnat, Michael D
Gainer, Julie
Bawdon, Roger E
Wendel, George D
author_sort Hnat, Michael D
collection PubMed
description OBJECTIVES: To determine maternal-fetal transplacental passage of vancomycin in the ex vivo human placental perfusion model. METHODS: Six term placentas were collected immediately after delivery and perfused with physiologic medium using the single cotyledon perfusion system. Vancomycin was added to the maternal medium and perfused through the maternal circulation of the cotyledon. Over a 1-h period in an open system, samples of the perfusate were collected at defined intervals from the fetal venous catheter and from the maternal effluence to assess vancomycin transfer. Thereafter, the system was closed for 1-5 h to establish accumulation. Transport fraction and clearance indexes were calculated by perfusing antipyrine 14C (positive control). Vancomycin was estimated by high pressure liquid chromatography and antipyrine 14C concentration was determined by liquid scintillation. RESULTS: Mean vancomycin maternal peak and trough concentrations ranged from 30.0 to 51.5 microg/ml and 7.7 to 16.4 microg/ml, respectively. Clearance indexes were minimal with a mean peak range of 0.000-0.080 and a mean trough range of 0.00-0.17. For each placenta, transport fraction for antipyrine 14C was > 1.85 with a single pass of > 40%. No accumulation of vancomycin was noted when the system was closed for 1-5 h. The mean peak clearance index was zero after perfusing the placenta for up to 5 h with 35.8 microg/ml of vancomycin. CONCLUSION: Transplacental passage of vancomycin was minimal in the ex vivo human placental perfusion model, with no detectable accumulation.
format Text
id pubmed-1784591
institution National Center for Biotechnology Information
language English
publishDate 2004
record_format MEDLINE/PubMed
spelling pubmed-17845912007-02-05 Transplacental passage of vancomycin in the ex vivo human perfusion model. Hnat, Michael D Gainer, Julie Bawdon, Roger E Wendel, George D Infect Dis Obstet Gynecol Research Article OBJECTIVES: To determine maternal-fetal transplacental passage of vancomycin in the ex vivo human placental perfusion model. METHODS: Six term placentas were collected immediately after delivery and perfused with physiologic medium using the single cotyledon perfusion system. Vancomycin was added to the maternal medium and perfused through the maternal circulation of the cotyledon. Over a 1-h period in an open system, samples of the perfusate were collected at defined intervals from the fetal venous catheter and from the maternal effluence to assess vancomycin transfer. Thereafter, the system was closed for 1-5 h to establish accumulation. Transport fraction and clearance indexes were calculated by perfusing antipyrine 14C (positive control). Vancomycin was estimated by high pressure liquid chromatography and antipyrine 14C concentration was determined by liquid scintillation. RESULTS: Mean vancomycin maternal peak and trough concentrations ranged from 30.0 to 51.5 microg/ml and 7.7 to 16.4 microg/ml, respectively. Clearance indexes were minimal with a mean peak range of 0.000-0.080 and a mean trough range of 0.00-0.17. For each placenta, transport fraction for antipyrine 14C was > 1.85 with a single pass of > 40%. No accumulation of vancomycin was noted when the system was closed for 1-5 h. The mean peak clearance index was zero after perfusing the placenta for up to 5 h with 35.8 microg/ml of vancomycin. CONCLUSION: Transplacental passage of vancomycin was minimal in the ex vivo human placental perfusion model, with no detectable accumulation. 2004-06 /pmc/articles/PMC1784591/ /pubmed/15739818 Text en
spellingShingle Research Article
Hnat, Michael D
Gainer, Julie
Bawdon, Roger E
Wendel, George D
Transplacental passage of vancomycin in the ex vivo human perfusion model.
title Transplacental passage of vancomycin in the ex vivo human perfusion model.
title_full Transplacental passage of vancomycin in the ex vivo human perfusion model.
title_fullStr Transplacental passage of vancomycin in the ex vivo human perfusion model.
title_full_unstemmed Transplacental passage of vancomycin in the ex vivo human perfusion model.
title_short Transplacental passage of vancomycin in the ex vivo human perfusion model.
title_sort transplacental passage of vancomycin in the ex vivo human perfusion model.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784591/
https://www.ncbi.nlm.nih.gov/pubmed/15739818
work_keys_str_mv AT hnatmichaeld transplacentalpassageofvancomycinintheexvivohumanperfusionmodel
AT gainerjulie transplacentalpassageofvancomycinintheexvivohumanperfusionmodel
AT bawdonrogere transplacentalpassageofvancomycinintheexvivohumanperfusionmodel
AT wendelgeorged transplacentalpassageofvancomycinintheexvivohumanperfusionmodel